Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (August 2020)
19 slides from Genetic Signatures's investor presentation, August 2020
Slide 1: Investor presentation
Investor presentation August 2020
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Genetic Signatures Limited (“GSS”). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is propr
Slide 3: Investment highlights
Investment highlights Trusted and proven Significant opportunity Competitive advantage technology created by COVID-19 100% customer retention since 2016 Underpinned by novel 3baseTM Leverage internal capabilities to and the accuracy of the technology technology providing increased develop a ne
Slide 4: Outstanding year against the backdrop of COVID-19, reflected by positive share price performance
Genetic Signatures has had an outstanding year against the backdrop of the COVID-19 pandemic, reflected by positive share price performance FY20 FY21 focus Share Price (A$) Jul-20: Jun-20: Record 4Q • 1Q FY21 on track to 3.00 Included in and FY20 report sales growth of Apr-20: S&P/ASX All revenue +2
Slide 5: Significant revenue growth and a milestone quarter in 4Q FY2020
Significant revenue growth and continued to achieve strong year-on- year revenue growth and a milestone quarter in 4Q FY2020 Revenue (A$m) Exceptional year for Genetic Signatures 59% core revenue +131% Revenue for FY20 of $11.3m, a +131% on pcp CAGR (FY17-20) 11.3 Record quarterly revenue in 4Q
Slide 6: Financial performance
Financial performance Year ending Year ending A$000 30 June 2020 30 June 2019 • Revenue of $11.3m ,+131% on pcp driven by Sales revenue 11,263 4,866 demand for SARS-CoV-2 test Other income 2,910 2,327 ‒ Other revenue includes R&D tax rebate of $2.6m Total revenue 14,173 7,193 • Expense up ~35% relat
Slide 7: Trusted and proven technology – EasyScreen products built on 3base technology
Trusted and proven technology – the EasyScreenTM products are built on 3baseTM technology Our Products Transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays. Our automated sample preparation method is suitable for bac
Slide 8: Global market size of ~A$10bn per annum
Broad suite of EasyScreenTM Detection Kits targeting significant addressable markets EasyScreenTM Products Enteric Respiratory ESBL & CPO STI / Genital Alphavirus / Meningitis Atypical Includes SARS-Cov-2 (“Superbug”) Flavivirus Respiratory Detection Kits Global market size of ~A$10bn per annum Sour
Slide 9: Rapid development of SARS-CoV-2 kit and scaled up manufacturing capacity
Rapid development of SARS-CoV-2 kit and scaled up manufacturing capacity to meet a significant increase in customer demand Strongly positioned to test for SARS-CoV-2 EasyScreenTM SARS-CoV-2 Detection Kit update CE-IVD and TGA received – kits available for The SARS-CoV-2 Test can be used alone or s
Slide 10: Competitive advantage - 3base technology creates benefits for multiple key stakeholders
Competitive advantage - Genetic Signatures’ 3baseTM technology creates potential benefits for multiple key stakeholders qPCR1 detection methodology used, the gold standard for infectious disease diagnosis Rapid time to results, with results processed from 4 hours, for up to 188 specimens Scree
Slide 11: Growth underpinned by scalable revenue model and attractive unit economics
Growth underpinned by scalable revenue model and attractive unit economics supported by expanding pipeline of new customers / tenders Attractive revenue model High throughput with Sticky annuity Attractive return on predictable orders revenue investment Target high throughput “Printer & cartri
Slide 12: Global strategy for commercialisation - COVID-19 created opportunity to accelerate international expansion
Global strategy for commercialisation - COVID-19 pandemic has created an opportunity to accelerate international expansion 2 EMEA: Focused on increasing customer acquisitions • CE-IVD received for SARS-CoV-2 kit and product launched • New customers established, including 3 new distributors • 4 test
Slide 13: On track to achieve multiple commercial milestones in FY21
On track to achieve multiple commercial milestones in FY21 that could accelerate revenue growth Near term CE-IVD received allowing marketing of the kit in Europe with orders received opportunities for TGA registration received allowing marketing of the kit in Australia with orders received SARS-
Slide 14: Appendices
Genetic Signatures Transforming Molecular Diagnostics Appendices
Slide 15: A global leader in the supply of molecular diagnostic solutions
A global leader in the supply of molecular diagnostic solutions A specialist molecular diagnostics company Share price (A$) Volume (m) 3.0 2.5 Focused on becoming a global leader in the supply of molecular diagnostic solutions 2.4 2.0 Developing and commercialising its proprietary 1.8 1.5 platform t
Slide 16: Novel proprietary technology - 3base platform underpins the EasyScreen product range
Novel proprietary technology - proprietary 3baseTM platform technology underpins the EasyScreenTM product range Our proprietary 3baseTM solution… …improves workflow and increases throughput 1 3baseTM platform technology converts original EasyScreen™ kits are compatible with 4-base microbial genome t
Slide 17: Board of Directors with proven track records of commercialisation success
Board of Directors with proven track records of commercialisation success across key geographic regions • Significant experience in leading international sales expansions of biotech companies Nick Samaras • Former Managing Director of Applied Biosystems (acquired by ThermoFisher, US$76.8bn Non-Execu
Slide 18: International management team of highly skilled researchers and executives
International management team of highly skilled researchers and executives bring a broad array of experience and knowledge • One of the pioneers of the bisulphite genomic sequencing protocol with a PhD in Molecular Genetics Dr. Doug Millar • Key inventor on over 30 patents or pending patent applicat
Slide 19: Contact us
Contact us Dr John Melki Peter Manley Genetic Signatures Genetic Signatures Chief Executive Officer Chief Financial Officer P: +61 (0)2 9870 7580 P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com E: peter.manley@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social med
Genetic Signatures — Investor Presentation (August 2020) on 6ix